Navigation Links
Cephalon Reports Record Earnings and Raises 2010 Guidance
Date:10/28/2010

(4)(12)Generic OTFC

32,609-32,60966,834-66,834(51)0(51)Other Generic Pain

-42,73842,738-6,2596,2590583583Pain

273,366108,289381,655307,01961,492368,511(11)764OncologyProprietary OncologyTREANDA

284,900-284,900160,549-160,54977-77Other Proprietary Oncology

15,93157,29073,22113,53053,73367,2631879Generic Oncology

-15,41015,410-14,68514,685-55Oncology

300,83172,700373,531174,07968,418242,49773654OtherOther Proprietary

11,2224,10815,33013,277-13,277(15)-15Other Generic

10,680199,122209,80212,88981,58394,472(17)144122Other

21,902203,230225,13226,16681,583107,749(16)149109$  1,533,322$
462,871$  1,996,193$  1,308,412$
280,198$  1,588,61017%65%26% Europe- Primarily Europe, Middle East and Africa Proprietary products are products which are sold under patent coverage.   Generic products are products sold without patent coverage in the primary sales territory. Patent coverage may exist in other territories.   CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except share data)(Unaudited)September 30, December 31, 20102009CURRENT ASSETS:   Cash and cash equivalents

$
,208,990$
,647,635   Receivables, net

450,614376,076   Inventory, net

295,880240,576   Deferred tax assets, net

225,031243,246   Other current assets

66,78758,423Total current assets

2,247,3022,565,956   INVESTMENTS

12,59412,427   PROPERTY AND EQUIPMENT, net

500,013451,879   GOODWILL

833,358590,284   INTANGIBLE ASSETS, net

1,234,181981,857   DEBT ISSUANCE COSTS

15,36218,862   OTHER ASSETS

43,58236,830$
4,886,392$
4,658,095CURRENT LIABILITIES:   Current portion of long-term debt, net

$
44,097$
818,925   Accounts payable

100,91788,829   Accrued expenses

507,408430,209Total current liabilities

<
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
3. Cephalon Completes Acquisition of Arana Therapeutics
4. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Cephalons New Product Launches Pace Record 2008 Sales
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... GMO corn cases filed across the ... in the process of being consolidated in a Kansas ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... District of Kansas. , Management of the Syngenta GMO ... U.S. District Judge John W. Lungstrum.* , As a ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today announced ... on Tuesday, November 6, 2007,following the close of the ... call and live audio webcast to discuss the,quarterly results ... p.m.,Eastern Time/2:00 p.m. Pacific Time. The live webcast ...
... Oct. 24 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX:,ATB) ... at 10 a.m. Eastern,time on November 8, 2007. ... 2007 third quarter results issued earlier the previous ... following numbers:,416-644-3418, 514-807-8791 or 800-591-7539 or via the ...
... IRVINE, Calif., Oct. 24 Cardiogenesis,Corporation (OTC: CGCP), ... third quarter ended September 30, 2007 prior to ... also said that President Richard,P. Lanigan and Senior ... will host an investor conference call that day ...
Cached Biology Technology:Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007 2Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8 2Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th 2
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... University,s work in protecting the lives and livelihoods of some ... prestigious national award. At the Times Higher Education awards ... the School of Planning, Architecture and Civil Engineering received the ... award recognises the team,s work in tackling the world,s worst ...
... the University of Leicester have identified for the first time ... of sugar in our blood following a meal. ... in helping to maintain correct blood sugar levels. The ... team led by Professor Andrew Tobin, Professor of Cell Biology, ...
... Universitaet Muenchen (TUM) have formed a strategic alliance for catalysis ... field of catalysis, a major aspect of this cooperation will ... to help meet the rising global demand for energy and ... this research work with up to two million euros a ...
Cached Biology News:Queen's life-saving research wins education 'Oscar' 2Up to 20 million euros for Munich Catalysis research cooperation 2Up to 20 million euros for Munich Catalysis research cooperation 3
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
... Secondary Detection System is intended for use ... Antibody reagents, which contain rat and goat ... by light microscopy in paraffin-embedded tissues. The ... also be used with other rat or ...
... Lower operational costs. More efficient interfacing ... limited sample volumes. Industry demands for ... using microbore chromatography for routine applications. ... adequately satisfy the need to operate ...
... The Hepta adaptor for the PDS-1000 He ... be transformed than the standard system. It fits ... system, where it splits the helium shock wave ... gold or tungsten particles over this larger area, ...
Biology Products: